Status:
COMPLETED
A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers
Lead Sponsor:
AbbVie
Conditions:
Hepatitis C Virus (HCV)
Eligibility:
All Genders
18+ years
Brief Summary
Hepatitis C Virus is liver disease and is a leading cause of death and morbidity with around 71 million people affected worldwide. Widespread availability of highly effective direct-acting antivirals ...
Eligibility Criteria
Inclusion
- Followed in an addiction center.
- Confirmed positive for HCV ribonucleic acid (RNA).
Exclusion
- None.
Key Trial Info
Start Date :
May 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT04366973
Start Date
May 26 2020
End Date
December 31 2023
Last Update
February 1 2024
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de soin d'accompagnement et de prevention en addictologie- CHU Archet 2 /ID# 218682
Nice, Alpes-Maritimes, France, 06200
2
Centre de Soins d'Accompagnement et de Prevention en Addictologie-Tempo Oppelia /ID# 218701
Valence, Drome, France, 26000
3
CSAPA Bagnols sur ceze /ID# 233397
Bagnols-sur-Cèze, Gard, France, 30200
4
Centre de soin d'accompagnement et de prevention en addictologie- L'ENVOL /ID# 218680
Nîmes, Gard, France, 30900